Hillel Galitzer - Entera Bio COO

ENTX
 Stock
  

USD 1.86  0.04  2.20%   

  COO
Dr. Hillel Galitzer is Chief Operating Officer of the company since February 2014, and prior to that served as our Director of Scientific Development from July 2012. Between August 2010 and February 2014, Dr. Galitzer was an analyst and the chief operating officer for Hadasit Bio Holdings Ltd., a publicly traded company on the Tel Aviv Stock Exchange and OTC markets. He has more than 10 years of experience in medical research and molecular biology. He is the cofounder and former chief operating officer of Optivasive Inc. He has written numerous publications in peerreviewed journals and has lectured and presented in international conferences and universities
Age: 38  COO Since 2014  MBA    
972 2 532 7151  https://www.enterabio.com
Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation, his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem.

Hillel Galitzer Latest Insider Activity

Tracking and analyzing the buying and selling activities of Hillel Galitzer against Entera Bio stock is an integral part of due diligence when investing in Entera Bio. Hillel Galitzer insider activity provides valuable insight into whether Entera Bio is net buyers or sellers over its current business cycle. Note, Entera Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Entera Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Entera Bio Management Efficiency

Entera Bio has return on total asset (ROA) of (41.97) % which means that it has lost $41.97 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (99.97) %, meaning that it created substantial loss on money invested by shareholders. Entera Bio management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Invested Capital is likely to rise to 5.50 in 2022, whereas Return on Average Assets are likely to drop (0.51)  in 2022. Entera Bio Assets Non Current are fairly stable at the moment as compared to the past year. Entera Bio reported Assets Non Current of 658,000 in 2021. Goodwill and Intangible Assets is likely to rise to about 556.5 K in 2022, whereas Total Assets are likely to drop slightly above 21.9 M in 2022.
The company currently holds 240 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Entera Bio has a current ratio of 9.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Entera Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Entera Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Entera Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Entera to invest in growth at high rates of return. When we think about Entera Bio's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

COO Since

Paul McKenzieCsl Ltd ADR
2019
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people. Entera Bio (ENTX) is traded on NASDAQ Exchange in USA. It is located in Kiryat Hadassah Minrav Building and employs 21 people. Entera Bio was previously known as Entera Bio and was traded on NASDAQ Exchange under the symbol ENTXW. Entera Bio is listed under Pharmaceutical Products category by Fama And French industry classification.

Entera Bio Leadership Team

Elected by the shareholders, the Entera Bio's board of directors comprises two types of representatives: Entera Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Entera. The board's role is to monitor Entera Bio's management team and ensure that shareholders' interests are well served. Entera Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Entera Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
Hillel Galitzer, COO
Miranda Toledano, Independent Director
Sean Ellis, Director
Dana YaacovGarbeli, Interim CFO
Gerald Ostrov, Independent Director
Chaim Davis, Director
David Ami, Director
Zeev Bronfeld, Director
Adam Gridley, CEO
Yeonatan Malca, Director
Mira Rosenzweig, CFO
Roger Garceau, Director
Faith Charles, Independent Director
Phillip Schwartz, CEO, Director
Arthur Santora, Chief Medical Officer
Gerald Lieberman, Chairman of the Board
Miriam Blum, Chief Medical Officer

Entera Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Entera Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Entera Bio without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Shere Portfolio Now

   

Shere Portfolio

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Pair Trading with Entera Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entera Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will appreciate offsetting losses from the drop in the long position's value.

Moving against Entera Bio

0.86DYAIDyadic International Earnings Call  This WeekPairCorr
0.8CVMCel-Sci Corp Fiscal Year End 28th of December 2022 PairCorr
0.73KTRAKintara Therapeutics Fiscal Year End 5th of October 2022 PairCorr
0.72KDNYChinook Therapeutics Earnings Call  TodayPairCorr
The ability to find closely correlated positions to Entera Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entera Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entera Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entera Bio to buy it.
The correlation of Entera Bio is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entera Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entera Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entera Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Investing Opportunities. Note that the Entera Bio information on this page should be used as a complementary analysis to other Entera Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Entera Stock analysis

When running Entera Bio price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
52.4 M
Quarterly Revenue Growth YOY
-0.57
Return On Assets
-0.42
Return On Equity
-1.0
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Entera Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.